Orphan Drug Coverage In Exchange Plans Explored In Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Researchers from Avalere and the National Organization for Rare Disorders find orphan drugs that are the only products in their class, such as Amgen’s Sensipar, have “relatively robust” coverage in a selection of popular health plans sold through exchanges in 15 states.